- Home
- CYBN vs VXRT Comparison
CYBN vs VXRT Comparison
Compare CYBN & VXRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBN
- VXRT
- Stock Information
- Founded
- CYBN 2019
- VXRT N/A
- Country
- CYBN Canada
- VXRT United States
- Employees
- CYBN N/A
- VXRT N/A
- Industry
- CYBN Pharmaceuticals and Biotechnology
- VXRT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CYBN Health Care
- VXRT Health Care
- Exchange
- CYBN Nasdaq
- VXRT Nasdaq
- Market Cap
- CYBN 127.3M
- VXRT 119.0M
- IPO Year
- CYBN N/A
- VXRT N/A
- Fundamental
- Price
- CYBN $7.96
- VXRT $0.43
- Analyst Decision
- CYBN Strong Buy
- VXRT Strong Buy
- Analyst Count
- CYBN 4
- VXRT 2
- Target Price
- CYBN $86.00
- VXRT $3.00
- AVG Volume (30 Days)
- CYBN 326.6K
- VXRT 1.8M
- Earning Date
- CYBN 06-25-2025
- VXRT 05-13-2025
- Dividend Yield
- CYBN N/A
- VXRT N/A
- EPS Growth
- CYBN N/A
- VXRT N/A
- EPS
- CYBN N/A
- VXRT N/A
- Revenue
- CYBN N/A
- VXRT $47,395,000.00
- Revenue This Year
- CYBN N/A
- VXRT N/A
- Revenue Next Year
- CYBN N/A
- VXRT N/A
- P/E Ratio
- CYBN N/A
- VXRT N/A
- Revenue Growth
- CYBN N/A
- VXRT 433.43
- 52 Week Low
- CYBN $4.81
- VXRT $0.29
- 52 Week High
- CYBN $13.88
- VXRT $1.07
- Technical
- Relative Strength Index (RSI)
- CYBN 61.23
- VXRT 48.78
- Support Level
- CYBN $7.00
- VXRT $0.44
- Resistance Level
- CYBN $8.50
- VXRT $0.48
- Average True Range (ATR)
- CYBN 0.53
- VXRT 0.04
- MACD
- CYBN 0.15
- VXRT -0.00
- Stochastic Oscillator
- CYBN 76.00
- VXRT 37.12
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.
About VXRT Vaxart Inc
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.